CEO of Beigene (30-Year Financial, Insider Trades) John Oyler (insider trades) sold 40,559 shares of BGNE on 08/04/2020 at an average price of $221.27 a share. The total sale was $9 million.
BeiGene Ltd is a biopharmaceutical company engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-A317 and BGB-290 and one immuno-oncology agent. BeiGene Ltd has a market cap of $20.22 billion; its shares were traded at around $227.01 with and P/S ratio of 34.67. GuruFocus has detected 3 severe warning signs with BeiGene Ltd. .
CEO Recent Trades:
- CEO John Oyler sold 17,254 shares of BGNE stock on 08/05/2020 at the average price of $223.27. The price of the stock has increased by 1.68% since.
- CEO John Oyler sold 40,559 shares of BGNE stock on 08/04/2020 at the average price of $221.27. The price of the stock has increased by 2.59% since.
- CEO John Oyler sold 27,748 shares of BGNE stock on 07/22/2020 at the average price of $238.34. The price of the stock has decreased by 4.75% since.
- CEO John Oyler sold 55,175 shares of BGNE stock on 07/21/2020 at the average price of $251.84. The price of the stock has decreased by 9.86% since.
- CEO John Oyler sold 53,914 shares of BGNE stock on 07/08/2020 at the average price of $199.12. The price of the stock has increased by 14.01% since.
Directors and Officers Recent Trades:
- CMO, Hematology Jane Huang sold 3,000 shares of BGNE stock on 07/29/2020 at the average price of $209.93. The price of the stock has increased by 8.14% since.
- President & GM China Xiaobin Wu sold 3,300 shares of BGNE stock on 07/20/2020 at the average price of $249.22. The price of the stock has decreased by 8.91% since.
- Chair, Scientific Advisory Brd Xiaodong Wang sold 17,000 shares of BGNE stock on 07/20/2020 at the average price of $251.51. The price of the stock has decreased by 9.74% since.
- President & GM China Xiaobin Wu sold 5,700 shares of BGNE stock on 07/15/2020 at the average price of $230. The price of the stock has decreased by 1.3% since.
For the complete insider trading history of BGNE, click here
.
